Hyperion DeFi, Inc. (HYPD) Stock

Hyperion DeFi, Inc. (HYPD) is a Healthcare stock trading at $3.16 (as of 2026-08-21), with a market capitalization of $47.90M and a trailing P/E of 14.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

A U.S.-based firm pivoting from ophthalmic drug-delivery tech (Optejet) to becoming the first Nasdaq-listed U.S. company with a cryptocurrency treasury denominated in HYPE tokens from the Hyperliquid blockchain; also operates a validator (“Kinetiq × Hyperion”) and continues DeFi staking strategies alongside ongoing development of Optejet UFD™ for eye care.

Understand Hyperion DeFi, Inc.: how it makes money

Hyperion DeFi, Inc. develops ophthalmic drug delivery technology (Optejet) and also manages a cryptocurrency treasury denominated in HYPE tokens from the Hyperliquid blockchain, earning money through DeFi staking and validator activity tied to several monetization revenue lines.

The company’s monetization model is structured around converting a HYPE-token cryptocurrency treasury, plus validator participation, into labeled DeFi income streams such as yield enhancement, D-Time monetization, ecosystem rewards, and related digital-asset treasury revenue, while Optejet development continues as a separate track.

Revenue by segment (latest quarter)
YieldEnh	$0.0B
DTime	$0.0B
Ecosys	$0.0B
DigTreRev	$0.0B

Business quality (Strong): The provided facts describe the business model clearly, but the financial dataset shown (for 2026-03-31) reports 0.0B revenue across the listed revenue-line items, and no official reportable segment definitions are provided beyond those revenue labels.

Bull case

Token-delegation and validator activity are explicitly part of the operating framework, with metrics provided for tokens delegated and validator-related earnings: Operationally, the business is set up to generate value from staking and validator participation on the Hyperliquid blockchain using HYPE tokens held in the treasury.
The company operates both a validator (Kinetiq × Hyperion) and continues DeFi staking strategies, alongside ongoing Optejet UFD development: This creates two visible workstreams: blockchain-based staking monetization and continued technology development for eye care.

Bear case

Reported revenue-line items for the latest period are shown as 0.0B across the provided categories: If monetization is not materializing in reported results, investors may have difficulty connecting staking participation to reported revenue.
The business explicitly centers on a cryptocurrency treasury denominated in HYPE tokens and monetization tied to DeFi activities on the Hyperliquid blockchain: That structure can make outcomes dependent on how staking and validator economics play out in the token and network environment.

Valuation — source: SEC EDGAR (first-party)
Price	$3.16
Market Cap	$47.90M
P/E Ratio	14.6
EV / EBITDA	22.8
Price / Book	0.82
Price / Sales	82.10
FCF Yield	-16.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$813455.00
Net Margin	-5570.6%
Revenue Growth (YoY)	1318.8%
EPS Growth (YoY)	-84.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-7.35 (distress)

Valuation vs Sector & Industry
Stock P/E	14.6
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-32.9%
vs Industry	-14.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	MORGAN STANLEY ($821051.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Hyunsu Jung
Employees	13
Country	US
IPO Date	2025-07-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.